PDCD1 and cancer: However, our results showed that TF is capable of markedly decreasing PD‐L1 expression on the surface of cancer cells, which subsequently disrupts its interaction with PD‐1 on T cells and reinvigorates the antitumor immune response, suggesting its broad potential in tumor immunotherapy.